Amicrobe specializes in the design, patenting, and production of macro biologics, which are large molecule biologics characterized by their unique physical properties and functional activities. These innovative products are developed with a focus on being environmentally friendly and beneficial for various industries. The company's flagship technology, Amicidins™, represents a significant advancement in the field, aiming to address critical health challenges, particularly in combating antibiotic-resistant bacteria. This initiative is supported by various esteemed organizations, including the U.S. Department of Defense and the U.K. Global AMR Innovation Fund, highlighting the importance and potential impact of their work.

The company’s pipeline includes investigational products that are at the forefront of biopharmaceutical development, with ongoing support from multiple funding sources such as CARB-X and the U.S. Army Medical Research & Materiel Command. Amicrobe's commitment to innovation is evident in its collaborative approach, seeking partnerships to create new products and enhance existing ones. This strategic focus not only aims to improve health outcomes but also aligns with broader public health initiatives to combat antibiotic resistance, showcasing the company's dedication to advancing science for the betterment of society.

United States

Amicrobe is a biotechnology company that develops locally applied products using the Amicidins™ technology platform for preventing and treating life-threatening infections with reduced commercial risk.

Amicrobe

Company Details